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Abstract
Autism Spectrum Disorder (ASD) refers to a heterogenous neurological condition
characterized by repetitive and restrictive behaviors and social communication deficits. ASD
diagnoses are at a record high, at approximately 1 in 59 children according to the US Center
for Disease Control. Currently, there are no available interventions that effectively treat the
core symptoms of ASD. All pharmaceutical options address comorbid side effects of ASD
but not core deficits and are particularly associated with negative side effects. Additionally,
there are economic and geographic barriers that can prevent families of individuals with ASD
from seeking or receiving effective interventions. Many of the available interventions are
extremely costly, time-consuming, and age dependent. These factors, as well as others, have
led to an increase in families independently utilizing complementary and alternative
interventions. Due to the large amount of misinformation available on the Internet, families
have become more susceptible to trying alternative forms of interventions that have not been
scientifically proven as effective, and in some cases, are significantly detrimental. Thus, the
need for accessible and inexpensive evidence-based nonpharmaceutical interventions is
critical and must be addressed. Fortunately, recent groundbreaking research has discovered
two strains of probiotics, Bacteroides fragilis and Lactobacillus reuteri, that have been
shown to ameliorate behavioral and social deficits respectively, in validated ASD mouse
models in a non-age-dependent manner. Probiotic intervention with a combination of these
specific strains would effectively target both repetitive behaviors and social deficits, core
ASD symptoms, and provide families with an accessible and inexpensive form of
intervention. The mechanisms underlying the efficacy of these probiotics are thought to be
associated with the gastrointestinal (GI) system and the oxytocin pathway. This study seeks
to examine the necessity of accessible nonpharmaceutical interventions and to provide an
effective intervention that is neither expensive or age dependent. This study also aims to
provide greater insight into the pathways and systems in which these probiotics operate.
i

I. Introduction
Autism spectrum disorder (ASD) is a pervasive neurodevelopmental disorder that
encompasses a wide range of pathology. The most recent estimate of the incidence of autism
in America is from the Center of Disease Control and Prevention (CDC, 2018) in 2014. The
CDC’s Autism and Developmental Disabilities Monitoring (ADDM) estimates that about 1
in 59 children has been diagnosed with ASD. Studies in Asia, Europe, and North America
have estimated an average prevalence of ASD as between 1%-2% (CDC, 2018). The
estimated worldwide incidence rate is about 1% (Lai, Lombardo, & Baron-Cohen, 2014).
ASD diagnoses are at a historic high and with such a large population of individuals, ASD
and ASD treatments have gained greater importance.
Additionally, the financial burden that accompanies a diagnosis of autism is
astonishingly excessive. It is estimated that in the United States, the total costs per year for
children with ASD falls between $11.5 billion- $60.9 billion (2011 US dollars) (CDC, 2018).
This number includes a variety of direct and indirect costs from medical care, loss of parental
economic productivity, and special education (CDC, 2018). On average, the average medical
expenditures of children and adolescents with ASD exceeded those without ASD by $4,110$6,200 per year, approximately 4.1-6.2 times greater (CDC, 2018). In addition to medical
expenditures, general expenditures were 8.4-9.5 times greater for children and adolescents
with ASD, in comparison to those without (CDC, 2018). In 2005, the average annual medical
costs for Medicaid-enrolled children with ASD were $10,709 per child, while the average
costs for children without ASD was $1,812, approximately six times less (CDC, 2018). Early
intensive behavioral interventions, one of the most effective interventions available, can cost
between $40,000-$60,000 annually per child (CDC, 2018). Thus, ASD places a huge
1

economic burden on affected families and there is a dire need for more affordable treatment
options as ASD indiscriminately affects families of all socio-economic levels.
Before the widespread application of early intervention programs, studies showed that
58%-78% of adults with autism had poor or very poor outcomes in terms of independent
living, educational attainment, employment, and peer relationships (Lai, Lombardo, &
Baron-Cohen, 2014). Only 46% of adults with autism are employed (regular, supported, or
sheltered) (Lai, Lombardo, & Baron-Cohen, 2014). Creating an accessible and inexpensive
non-pharmaceutical intervention that is not time-sensitive, like previous interventions that
must be applied early in life to be effective, will allow adults with ASD to increase their
independence and better their life outcomes. This would also decrease the large financial
responsibility associated with the life-long care of dependent adults with ASD.
Currently, there are no available treatment options for individuals with ASD that are
both inexpensive and easily accessible. However, recent research and its resulting
revolutionary evidence points to a promising new avenue of intervention; the use of
probiotics. There are two specific probiotic strains that have been identified as having the
potential to become a relatively accessible and affordable means of intervention for
individuals with ASD; Bacteroides fragilis and Lactobacillus reuteri. Furthermore, evidence
shows that intervention with these particular probiotic strains may improve the core
symptoms of ASD, deficits in social communication and repetitive behavior, a feat that has
not been accomplished by any of the current treatment options available to those with ASD
(Hsiao et al., 2013; Buffington et al., 2016; Sgritta et al., 2019).
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II. Background
1.Autism Spectrum Disorder
Symptoms
The hallmark symptoms of ASD are difficulties in social communication and social
interaction, and restricted, repetitive behavior, interests, or activities (APA, 2013). The
cognitive abilities of people with ASD can range from gifted to severely challenged,
representative of the wide range of symptomology and severity in ASD (CDC, 2018). About
45% of individuals with ASD have intellectual disability and 32% experience regression
(Lai, Lombardo, & Baron-Cohen, 2014). ASD is also associated with poor mental flexibility,
thought to be an underlying basis of repetitive behaviors and restrictive interests (Mišić et al.,
2015). Fixations tend to involve systems that operate deterministically and repeatably
according to salient sets of rules (Belmonte et al., 2014). Stereotyped movements and
compulsive and repetitive behavior are common and self-injurious behavior occurs in
approximately 30% of children with ASD (Amihaesei & Stefanachi, 2013). There are
different severities of speech impairments; some children never fully develop speech, or are
limited to echolalia (Belmonte et al., 2014). Communication impairment also includes
nonverbal signals such as gaze, facial expression, and gestures (Belmonte et al., 2014). Social
deficits involve difficulty with processing information of other people as well as selfreferential information (Lai, Lombardo, & Baron-Cohen, 2014). Other common symptoms
include sensory abnormalities, motor impairment, and alimentary abnormalities (Amihaesei
& Stefanachi, 2013). In addition, comorbidity is frequent in ASD populations; more than
70% of individuals with ASD have concurrent developmental, or psychiatric conditions (Lai,
Lombardo, & Baron-Cohen, 2014). Commonly associated comorbidities include intellectual
3

delay, epilepsy, metabolic syndromes, ADHD, Tourette syndrome, and sleep issues
(Amihaesei & Stefanachi, 2013). Headaches/migraines, respiratory issues, food allergies,
physician visits, prescription medication, and rate of infections are also more common in
children with ASD (Rodriguez & Kern, 2011). A meta-analytic study showed that the
mortality risk of individuals with ASD is 2.8 times higher than those without, despite
controlling for age and sex and is thought to be related to concurrent medical conditions (Lai,
Lombardo, & Baron-Cohen, 2014). Approximately 25% of children with ASD develop
seizures, although this is more common in girls with ASD than in boys with ASD. The
prevalence of sleep problems including disturbed sleep, decreased sleep duration, and
increased sleep onset delay, is higher in children with ASD than in children with intellectual
impairment (Belmonte et al., 2014). GI disorders are also more 3.5 times more prevalent in
children with ASD (Sharon, Sampson, Geschwind, & Mazmanian, 2016).
The numerous symptoms and comorbidities that accompany an ASD diagnosis often
cause some amount of impairment in independent living and sustaining social relationships.
Although impairment can range from nearly insignificant to considerably pronounced,
individuals with ASD face the common challenge of creating and maintaining social
relationships and managing restrictive and repetitive behavior. These core symptoms have
yet to be improved by any currently available interventions.
2.Diagnostic Criteria
To be diagnosed with ASD, certain clinical requirements, provided in the Diagnostic
and Statistical Manual of Mental Disorders (DSM) must be met. The most current version is
the DSM 5, published by the American Psychiatric Association (APA, 2013).
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The diagnostic criteria from the DSM 5 is as follows:
A. Persistent deficits in social communication and social interaction across multiple
contexts, as manifested by the following, currently or by history:
a. Deficits in social-emotional reciprocity
b. Deficits in nonverbal communication behaviors used for social interaction
c. Deficits in developing, maintaining, and understanding relationships

B. Restricted, repetitive patterns of behavior, interests, or activities, as manifested by at
least two of the following, currently or by history:
a. Stereotyped or repetitive motor movements, use of objects, or speech
b. Insistence on sameness, inflexible adherence to routines, or ritualized patterns
of verbal or nonverbal behavior
c. Highly restricted, fixated interests that are abnormal in intensity or focus
d. Hyper- or hyporeactivity to sensory input or unusual interest in sensory
aspects of the environment
C. Symptoms must be present in early development (but may not become fully manifest
until social demands exceed limited capacities or may be masked by learned
strategies in later life).
D. Symptoms cause clinically significant impairment in social, occupational, or other
important areas of current functioning.
E. These disturbances are not better explained by intellectual disability (intellectual
developmental disorder) or global developmental delay.

5

Accompanying the diagnosis is an assessment of severity, from one to three, with one being
the least severe and three being the most severe and is shown in Table 1 (APA, 2013).

An ASD diagnosis now encompasses several conditions that were formerly diagnosed
separately including: Asperger syndrome, typical autism, pervasive developmental disorder
not otherwise specified (PDD-NOS), Rett syndrome, and child disintegrative disorder (CDD)
which all vary in severity (CDC, 2018; Amihaesei & Stefanachi, 2013). ASD is
approximately four times more common amongst boys than girls, although it occurs in all
racial, ethnic, and socioeconomic groups (CDC, 2018). However, it is more common in
Caucasian children compared to African-American or Hispanic children (Bhat, Acharya,
Adeli, Bairy, & Adeli, 2014).
Early indicators of ASD include delays in verbal and nonverbal communication,
reciprocal affective behavior, joint attention and pretend play, atypical implicit perspective
6

taking, unusually repetitive behaviors, inflexibility in visual disengagement, and extreme
variation in temperament (Amihaesei & Stefanachi, 2013; Lai, Lombardo, & Baron-Cohen,
2014). Studies have shown that parents tend to notice a developmental problem before their
child’s first birthday if their child has ASD (CDC, 2018). Popular instruments used to aid in
diagnosis include the Autism Diagnosis Interview-Revised, the Autism Diagnosis
Observation Schedule, and the Childhood Autism Rating Scale (Amihaesei & Stefanachi,
2013). ASD diagnoses by clinicians are considered very reliable by the age of 2, although
most children with ASD are not diagnosed until after 4 (CDC, 2018).
There is a sizeable range of ages at which individuals receive their ASD diagnoses.
The variability in age at diagnosis can affect the opportunity of individuals with ASD to
receive early intensive behavioral intervention, currently the most effective intervention.
Thus, there is a clear need for an intervention that remains effective at all ages.
3.Etiology
The etiology of ASD is extremely complex and relatively unexplained, despite the
substantial amount of research dedicated to this topic of interest. There have been hundreds
of different factors implicated in the genesis of ASD, including environmental, biological,
and genetic factors (CDC, 2018). This expansive variety of known precipitators of ASD
parallels the extreme heterogeneity of the disorder. The critical period for developing ASD is
thought to be before, during, and immediately after birth (CDC, 2018).
Genetics
There is a strong genetic component to the genesis of autism and it has been well
researched. Over 90% of ASD incidence is estimated to be attributed to genetic factors
7

(Amihaesei & Stefanachi, 2013). Studies have shown extraordinary heterogeneity in ASD,
predicting hundreds of rare risk genes, none accounting for more than 1% of cases
(Peñagarikano et al., 2015). Researchers estimate that up to 1000 genes, with a high degree
of locus heterogeneity, are also implicated in ASD (Lai, Lombardo, & Baron-Cohen, 2014).
Many of the risk genes regulate synaptic functions of neurons that underly learning and
plasticity (Guastella and Hickie, 2016). Having a sibling with ASD increases risk of having
ASD; hereditary transmission in families with individuals with ASD is approximately 30%
(CDC, 2018; Amihaesei & Stefanachi, 2013). Certain genetic or chromosomal conditions
such as fragile X syndrome, Down’s syndrome, and tuberous sclerosis are correlated with
increased incidence of ASD (CDC, 2018). Around 10% of the ASD population have
comorbid genetic or chromosomal disorders (Bhat, Acharya, Adeli, Bairy, & Adeli, 2014).
Rare de novo mutations (copy number variations [CNVs] in the form of microdeletion or
microduplication, and nonsense, splice-site, and frame-shift mutations) have also been
implicated in the genesis of ASD (Lai, Lombardo, & Baron-Cohen, 2014; Bhat, Acharya,
Adeli, Bairy, & Adeli, 2014). For example, the mutation of CHD8 (chromodomain helicase
DNA binding protein 8) gene is linked to the development of ASD and results in
macrocephaly and wide set eyes (Bhat, Acharya, Adeli, Bairy, & Adeli, 2014). The large
network of genes affected by de novo CNVs are primarily related to synaptic development,
axon guidance, and neuron motility (Gilman et al., 2011; Bhat, Acharya, Adeli, Bairy, &
Adeli, 2014). Both large-effect rare mutations and small-effect common variants contribute
to risk of ASD (Lai, Lombardo, & Baron-Cohen, 2014). Rare mutations associated with ASD
can occur in the form of Mendelian genetic syndromes (also called syndromic autism),
chromosomal abnormalities, rare CNVs, and single nucleotide variants (Lai, Lombardo, &
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Baron-Cohen, 2014). In simplex cases, when only one individual in the family has autism, de
novo mutations are thought to be significant contributors to the genesis of ASD (Lai,
Lombardo, & Baron-Cohen, 2014). Genome-wide association studies have identified many
significant single nucleotide polymorphisms, but none of these have a large enough effect to
be causal (Lai, Lombardo, & Baron-Cohen, 2014). Gene networks regarding neuronal
function are under expressed in ASD while gene networks associated with immune function
are overexpressed (Lai, Lombardo, & Baron-Cohen, 2014). Many of the genes implicated in
ASD have a high degree of pleiotropy (one gene affects more than one phenotype) (Lai,
Lombardo, & Baron-Cohen, 2014). The gender discrepancy in the incidence of ASD is in
part explained by mutations in the X chromosome patched-related (PTCHD1) gene which
result in a recessive phenotype in girls and a dominant phenotype in boys (Falco, 2014). This
gene mutation has been implicated in the development of autism (Falco, 2014). Another
contributor, duplications in the 15q11-13 loci are also associated with ASD (Wagner). Gene
mutations can also affect the formation of cortex layers, resulting in cortical disorganization
(Bhat, Acharya, Adeli, Bairy, & Adeli, 2014).
Environment
Advanced parental age, both paternal and maternal, at the time of conception is
implicated in the development of ASD (Amihaesei & Stefanachi, 2013; CDC, 2018; Lai,
Lombardo, & Baron-Cohen, 2014). Gestational factors, such as gestational diabetes,
metabolic conditions, and obesity, also affect neurodevelopment and increase the likelihood
of ASD (Amihaesei & Stefanachi, 2013; Bhat, Acharya, Adeli, Bairy, & Adeli, 2014;
Buffington et al., 2016). Additional perinatal risk factors include: small birth weight, hypoxia
at birth, and mercury, radiation, and diesel exhaust exposure (Amihaesei & Stefanachi, 2013;
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Bhat, Acharya, Adeli, Bairy, & Adeli, 2014). The prescription drugs valproic acid and
thalidomide, taken during pregnancy, also increases risk of having a child with ASD, as well
as maternal viral infection (CDC, 2018; Bhat, Acharya, Adeli, Bairy, & Adeli, 2014;
Belmonte et al., 2014).
Recent evidence supports the association between ASD and extensive biological
systems dysregulation, the most significant being the gastrointestinal environment, immuneinflammation pathways, and nervous system (Azhari, Azizan, & Esposito, 2018; Belmonte et
al., 2014).
Immune System
Ongoing neuroinflammation in various brain regions has been found in children with
ASD (Rodriguez & Kern, 2011). This is supported by post-mortem brain examinations that
found elevated levels of activated microglia and astrocytes and irregular, proinflammatory
cytokine profiles (Rodriguez & Kern, 2011). Extended microglia activation increases the
production of mediators which results in a loss of synaptic connections, underconnectivity
and neuronal cell death (Rodriguez & Kern, 2011). Additionally, changes in major
histocompatibility complex (MHC) expression can lead to neurodevelopmental defects as
neurons in developing and adult brains express these proteins (Belmonte et al., 2014).
Cerebellar Purkinje cells are a site of MHC class 1 expression and they are significantly
reduced in number in ASD (Belmonte et al., 2014; Rodriguez & Kern, 2011) Decreased
expression of MHC class 1 impairs the pruning of inappropriate synaptic connections, which
could contribute to the increased brain volume of individuals with ASD at birth (Belmonte et
al., 2014). The abnormal immune-inflammation profile of individuals with ASD contributes
to the irregular organization and dysfunction of the nervous system.
10

Neurobiology
Atypical neural development at the systems level results in the atypical cognitive
profiles found in ASD, such as impaired social cognition and perception, executive
dysfunction, and atypical information processing (Lai, Lombardo, & Baron-Cohen, 2014).
The brain regions involved in social perception and cognition, including the medial
prefrontal cortex, superior temporal sulcus, temporoparietal junction, amygdala, and fusiform
gyrus, are hypoactive in ASD (Lai, Lombardo, & Baron-Cohen, 2014). However, recent
evidence supports the idea that ASD is characterized by atypical neural connectivity rather
than a discrete set of abnormal brain regions (Lai, Lombardo, & Baron-Cohen, 2014). The
brains of people with ASD are overdeveloped at birth as evidenced by increases in neuronal
count and synapses in key cortical zones, and unbalanced functioning of the neuronal
excitatory, versus inhibitory, networks (Amihaesei & Stefanachi, 2013). Increased brain
volume at birth is further specified as an excessive volume of cerebrum and cerebral white
matter with the greatest degree of enlargement in the frontal lobes and the least in the
occipital lobes (Belmonte et al., 2014). Abnormal early neurodevelopment includes early
postnatal brain overgrowth and subsequently stunted growth in both white and grey matter,
disorganization of cortical layers affecting both horizontal laminar compartments and vertical
columnar structure, and reduced functional and anatomical connectivity (Belmonte et al.,
2014, Nair et al., 2013). Aberrant organization and decreased coherence are a product of
differences in white matter microstructure, in both white matter tracts and the superior
temporal gyrus, in individuals with ASD (Mišić et al., 2015; Anderson et al., 2011).
Abnormalities in synaptic and columnar structure and neuronal migration, are also found in
the cerebral cortexes of ASD subjects (Bhat, Acharya, Adeli, Bairy, & Adeli, 2014). The
11

cortical areas that are essential to complex cognitive functions are the most affected and ASD
also affects the temporal organization of these areas which results in impaired cognitive set
shifting (Belmonte et al., 2014; Mišić et al., 2015). Cerebellar activation of ASD subjects
during cognitive tasks reflects the opposite of controls (Belmonte et al., 2014). There is also
increased cortical thinning in the frontal lobe, parietal lobe, occipital lobe, and cortex in ASD
(Zielinski et al., 2014). The functioning of the neural network involved in social and
emotional processing, including mirror neurons, is reduced in ASD and there are disruptions
in cortical response to dynamic social stimuli (Amihaesei & Stefanachi, 2013; Bhat,
Acharya, Adeli, Bairy, & Adeli, 2014).
Functional connectivity is significantly altered in ASD subjects and is represented in
Figure 1 (Amihaesei & Stefanachi, 2013; Rodriguez & Kern, 2011; Tyszka, Adolphs, Paul,
& Kennedy, 2013).
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Figure 1. The atypical functional connectivity of an autistic brain compared to a
neurotypical brain. (Bhat, Acharya, Adeli, Bairy, & Adeli, 2014)
The degree of connectivity abnormality is correlated with the severity of ASD
symptomology (Rodriguez & Kern, 2011). Functional and anatomical connectivity between
the cerebral cortex and thalamus shows bilateral impairment in ASD as well as between the
frontal lobe and other cortical regions (Nair et al., 2013; Amihaesei & Stefanachi, 2013;
Bhat, Acharya, Adeli, Bairy, & Adeli, 2014). Mišić et al. found that long-range functional
connectivity is reduced in ASD subjects (Mišić et al., 2015). High local connectivity is
another prominent feature of ASD, prominent in the cerebellum (Anderson et al., 2011;
13

Belmonte et al., 2014; Bhat, Acharya, Adeli, Bairy, & Adeli, 2014). Together, the high local
connectivity and low long-range connectivity result in atypical information processing
(Anderson et al., 2011; Bhat, Acharya, Adeli, Bairy, & Adeli, 2014; Mišić et al., 2015).
Interhemispheric correlation is also significantly reduced in regions with functional relevance
to ASD, but the largest difference was found in the anterior frontal insula which is a core
component of social processing networks (Anderson, Rodriguez & Kern, 2011). Dinstein et
al., found that toddlers with ASD had weak interhemispheric neural synchronization
(Dinstein et al., 2011). Verbal ability was positively correlated with strength of
synchronization while severity of ASD was negatively correlated (Dinstein et al., 2011). The
corpus callosum is also a site of significant abnormality in ASD subjects as its size is
decreased, resulting in decreased interhemispheric connection (Anderson et al., 2011;
Rodriguez & Kern, 2011).
4.Available Treatments
Through intervention and support, an individual’s functional independence and
quality of life can be maximized through learning and development, improved social skills
and communication, and reductions in disability and comorbidity (Lai, Lombardo, & BaronCohen, 2014). The most commonly used forms of therapy for ASD are Applied Behavior
Analysis (ABA), developmental models, structured learning techniques, speech therapy,
social skills therapy, and occupational therapy (Amihaesei & Stefanachi, 2013). Early
intensive behavioral interventions that are targeted and comprehensive can improve social
communication skills and reduce anxiety and aggression (Lai, Lombardo, & Baron-Cohen,
2014). Prescription medications can also be used in the treatment of ASD. The most
frequently prescribed medications are antidepressants, stimulatory drugs/psychotropes, and
14

antipsychotics (Amihaesei & Stefanachi, 2013). However, none of these drugs target core
ASD symptoms and instead treat the co-morbidities of ASD such as hyperactivity, anxiety,
and self-stimulatory behaviors (Wagner & Harony-Nicolas, 2018). Antipsychotic drugs have
been effective in reducing repetitive and aggressive behaviors in children with ASD (Lai,
Lombardo, & Baron-Cohen, 2014). Risperidone, an atypical antipsychotic, is the most widely
prescribed treatment for ASD although it only reduces hyperactivity, aggressive, selfinjurious, and repetitive behaviors and does not improve social deficits (Guastella and
Hickie, 2016). Risperidone has also been associated with significant side effects including
weight gain, drowsiness, extrapyramidal side effects, and hormonal changes related to
galactorrhea, amenorrhea, and gynecomastia (Guastella and Hickie, 2016). To date, no
biomedical agents have been shown to reliably improve social deficits (Lai, Lombardo, &
Baron-Cohen, 2014). Some unconventional therapies used in the treatment of ASD are:
acupuncture, antifungal therapy, art therapy, the Early Start Denver model, therapy with
dolphins, aerobics, interactive computer programs, facilitated communication, music therapy,
contact therapy, homeopathy, neuro-feedback, rhythms therapy, and yoga (Amihaesei &
Stefanachi, 2013). Despite their popularity and significant expense, these treatments have
little evidence to support their efficacy and are not specified for a subtype of ASD (Guastella
and Hickie, 2016). All available treatments are either lengthy, expensive, or time-sensitive
and do not alleviate core symptoms of ASD, highlighting the need for effective and
accessible interventions that address the core symptoms of ASD.
5.Animal Models of ASD
To establish effective evidence-based interventions for ASD, successful interventions
in animal models of ASD must be examined. Two common and validated animal models of
15

ASD are the Maternal Immune Activation (MIA) model and the Maternal High Fat Diet
(MHFD) model, used in the recent evidence to support probiotic intervention.
Maternal Immune Activation Model
The MIA mouse model is based on large epidemiological studies that linked maternal
infection to increased incidence of autism in offspring (Atladóttir et al., 2010). This model is
also supported by studies linking ASD risk to familial autoimmune disease and elevated
levels of inflammatory factors in the maternal blood, placenta, and amniotic fluid (Atladóttir
et al., 2010; Comi et al., 1999; Abdallah et al., 2013; Brown et al., 2004; Croen et al, 2008).
Stimulating maternal immune activation in mice triggers global changes in the gut
microbiome of offspring which is correlated with abnormal behavior, neuropathologies,
immune dysfunction, and GI impairment (Vuong & Hsiao, 2017). MIA in mice is stimulated
by injecting pregnant mice with the viral mimic poly (I:C) and results in offspring that
express core behavioral symptoms and neuropathologies of ASD (Malkova et al., 2012). The
offspring exhibit dysbiosis of gut microbiota, prominent in alterations of the bacterial classes
Clostridia and Bacteroidetes (Hsiao et al., 2013). The MIA offspring display ASD-like
behaviors, impaired intestinal integrity, and altered gut microbiome profiles (Hsiao et al.,
2013). These symptoms are comparable to similar endophenotypes found in subsets of
individuals with ASD (Hsiao et al., 2013).
Maternal High Fat Diet Model
The MHFD model is based on epidemiological studies that support a link between
maternal obesity and increased risk of neurodevelopmental disorders, such as ASD in
offspring (Connolly et al, 2016; Krakowiak et al., 2012; Sullivan). The MHFD triggers
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abnormal behavior in offspring and is mediated by alterations in the gut microbiome of the
offspring (Buffington et al., 2016). Buffington et al. found that the MHFD-induced changes
in the gut microbiome of offspring block long-lasting neural adaptation in the mesolimbic
dopamine reward system, specifically in the ventral tegmental area (VTA) (Buffington et al.,
2016). These neuronal adaptations enhance the salience of social stimuli and the MHFDinduced alterations in these neural networks results in social behavioral deficits (Buffington
et al., 2016). In comparison to offspring from mice fed a regular fat diet, MHFD offspring
had fewer reciprocal social interactions, impaired sociability, and lack of preference for
social novelty (Buffington et al., 2016). These offspring also exhibit repetitive behaviors and
anxiety, symptoms that are also associated with ASD, as well as fewer oxytocin
immunoreactive neurons in the hypothalamus (Buffington et al., 2016).
Utilizing these two validated animal models of ASD, two strains of probiotics have
been shown to successfully ameliorate behavioral and social deficits in affected offspring:
Bacteroides fragilis and Lactobacillus reuteri.

III. The Current State of Non-Pharmaceutical Interventions
Complementary and Alternative Medicine
Complementary and alternative medicine (CAM) is incredibly popular among
families with children with ASD (Akins, Angkustsiri, & Hansen, 2010). Examining nonpharmaceutical interventions is imperative as significant adverse side effects have been
associated with and increased by some conventional psychiatric medications used in children
with ASD (Akins, Angkustsiri, & Hansen, 2010). Additionally, families are often inclined to
17

search for more progressive and less expensive interventions, especially outside of the
medical field. Geographic and economic barriers can limit access to high-quality behavioral
and educational interventions, leaving families to find alternative forms of intervention
(Akins, Angkustsiri, & Hansen, 2010). The National Center for Complementary and
Alternative Medicine (NCCAM, 2013) defines CAM as “a group of diverse medical and
health care systems, practices, and products that are not generally considered part of
conventional medicine” (NCCAM, 2013). Complementary medicine is typically defined as
nontraditional treatments used in conjunction with conventional medicine, such using light
therapy to treat seasonal affective disorder in tandem with antidepressants (Akins).
Alternative medicine is defined as being used in place of conventional medicine, such as
using melatonin instead of sedatives to treat insomnia (Akins, Angkustsiri, & Hansen, 2010).
The American Academy of Pediatrics defines integrative medicine as “relationship-based
care that combines mainstream and complementary therapies for which there is some highquality scientific evidence of safety and effectiveness to promote health for the whole person
in the context of his or her family and community” (Kemper, Vohra, & Walls, n.d.). The
American Academy of Pediatrics also recommends the discussion of CAM with the family of
every ASD patient (Akins, Angkustsiri, & Hansen, 2010). CAM usage in children with ASD
is amongst the highest of any population with reported use between 52% and 95% in families
(Akins, Angkustsiri, & Hansen, 2010). Of families who have children with ASD and use
CAM treatments, approximately 50-70% choose a biologically based CAM treatment (Akins,
Angkustsiri, & Hansen, 2010). Parents of children with ASD reported current use of an
average of four treatment modalities and 80% reported some form of dietary intervention
(Lange, Hauser, & Reissmann, 2015). Qualitative studies have found that receiving outdated
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information for conventional systems of care, limited provider knowledge of their child’s
condition, parental frustration with discouraging prognoses, and attempts to construct an
alternative identity for their children and themselves increase CAM usage by parents of
children with disabilities (Akins, Angkustsiri, & Hansen, 2010). These findings highlight the
desire for families to gain more control over medical decision-making (Akins, Angkustsiri, &
Hansen, 2010). This desire coupled with geographic and economic barriers create a need for
effective non-pharmaceutical interventions in the treatment of ASD.
With the rise of the internet, online ASD support communities have become popular,
allowing parents to engage with other parents facing similar struggles and ASD-specific
information (Akins, Angkustsiri, & Hansen, 2010). However, internet usage also increases
families’ exposure to targeted marketing, testimonials, and unproven claims that could look
promising in the treatment of ASD (Akins, Angkustsiri, & Hansen, 2010). These ineffective
treatments exploit desperate parents and can even be dangerous. Some examples of dubious
popular treatments with negative side effects are: chelation therapy, antifungal agents,
hyperbaric oxygen therapy, and immune therapies including intravenous and oral Ig (Akins,
Angkustsiri, & Hansen, 2010). To date, chelation therapy, when used to treat symptoms of
ASD, has been linked with several deaths (Akins, Angkustsiri, & Hansen, 2010). There are
also many other purported treatments that are considered generally safe, but their efficacy is
unknown or even disproven such as use of multivitamins, secretin, and various amino acid
therapies (Akins, Angkustsiri, & Hansen, 2010).
Families of individuals with ASD are often searching for more effective alternatives
to pharmaceuticals. The high use of CAM shows that families are eager to do all they can and
desire to have more control over their situation. Additionally, some families cannot afford
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expensive treatments or are unable to access them, which also leads to higher CAM usage.
Instead of trying to suppress this phenomenon, researchers must try to meet the needs of
these families by creating an accessible and affordable alternative to pharmaceuticals or
lengthy behavioral therapy sessions. Due to increasing misinformation, the families of ASD
individuals are susceptible to making poor medical choices for their child, despite their best
intentions. Thus, the need for evidence-based intervention is imperative.
Efficacy of Gluten Free and Casein Free Diets
A product of misinformation, the gluten free and casein free diet (GFCF) has become
one of the most popular CAM treatments in children with ASD (Akins, Angkustsiri, &
Hansen, 2010). The GFCF diet is utilized in the treatment of ASD in 29% of families that use
dietary interventions; approximately 80% of families with ASD individuals (Lange, Hauser,
& Reissmann, 2015). The rationale for this diet remains unproven and is based on the “opioid
excess” theory which claims that individuals with ASD have impaired ability to break down
dietary proteins in gluten and casein, and that this results in the formation of opioid-like
peptides that cross the blood brain barrier (BBB) and contribute to the neurobehavioral
symptoms of autism (Akins, Angkustsiri, & Hansen, 2010). Parents have claimed that their
child’s GI symptoms (54%), concentration and attention (42%), communication (29%), and
social interaction (25%) improved after implementation of the GFCF diet (Lange, Hauser, &
Reissmann, 2015). However, it is important to address the measurement bias within these
findings as the parents were not blinded to the treatment and are likely hoping for their
child’s symptoms to improve, thus influencing their observations. The GFCF diet can be
difficult to implement as families face challenges such as increased food preparation time,
increased food-related expenses, and children refusing to eat the dietary selections (Akins,
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Angkustsiri, & Hansen, 2010). Additionally, further dietary restriction in a child with an
already limited food repertoire can induce negative behavioral and biological side effects
(Akins, Angkustsiri, & Hansen, 2010). In a study by Ghalichi et al., they showed that there
may be some potential of the GF diet to alleviate stereotyped behaviors and improve social
communication and interaction in some children with ASD (Ghalichi, Ghaemmaghami,
Malek, & Ostadrahimi, 2016). However, it is important to note that, once again, the parents
of the patients, who rated their child’s symptoms, were not blinded to the intervention and
thus could have been influenced by their awareness (Ghalichi, Ghaemmaghami, Malek, &
Ostadrahimi, 2016). Lange et al. did an in-depth meta-analysis of studies about the
intervention of GFCF diets on ASD symptoms (Lange, Hauser, & Reissmann, 2015). They
evaluated eight published case studies that included anecdotal case reports that attempted to
establish a casual role of gluten and casein in the pathology of ASD (Lange, Hauser, &
Reissmann, 2015). Lange et al. found that none of these studies used an appropriate
experimental control (Lange, Hauser, & Reissmann, 2015). It was also noted that all but two
studies found evidence of positive dietary effects of the GFCF diet for at least some of the
measures assessed and the two studies with null results were the case studies that met the
largest number of quality indicators of experimental validity (Lange, Hauser, & Reissmann,
2015). Lange et al, states that none of the case studies were conduced with adequate
scientific rigor and thus, the results of the studies can only be regarded as weak evidence at
best (Lange, Hauser, & Reissmann, 2015). Common issues included measurement bias, as a
result of relying on the subjective ratings of parents not blinded to the treatment, and lack of
appropriate control groups (Lange, Hauser, & Reissmann, 2015). Although the GFCF diet is
popular and there are a multitude of positive reviews from parents regarding its effects, most
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scientific studies have failed to confirm significant therapeutic effects (Lange, Hauser, &
Reissmann, 2015). It has been shown that there is an association between the casein-free diet
and bone loss in children, an alarming side effect that must be acknowledged with regard to
parental desire to implement the GFCF diet (Hediger et al., 2008). However, there may be a
possibility that there are specific subtypes of autism (possibly due to different genesis) that
may be sensitive and responsive to such dietary elements (Whiteley, 2017). As a concluding
thought, Lange et al., suggests that a GFCF diet should only be administered if an allergy or
intolerance to nutritional gluten or casein is diagnosed and present in the child with ASD
(Lange, Hauser, & Reissmann, 2015).
With the widespread prevalence of misinformation and the susceptibility of desperate
parents who want to help their children with ASD, evidence-based non-pharmaceutical
intervention is an incredibly important area of interest as it may help parents overcome
geographic and economic barriers and satisfy their desire for control and self-determination.
Additionally, an intervention based on strong evidence may prevent families from enduring
the financial and biological repercussions of implementing popular dietary interventions,
such as the GFCF diet, that have yet to be scientifically proven as effective.

IV. Probiotics of Interest
The two probiotic strains of interest in this proposed treatment of ASD are
Bacteroides fragilis and Lactobacillus reuteri.
1.Bacteroides Fragilis
Previously shown to correct colitis in infants, B. fragilis gained interest as a potential
probiotic intervention for individuals with ASD (Hsiao et al., 2013). In a groundbreaking
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experiment conducted by Hsiao et al, B. fragilis was discovered to correct gut permeability,
alter microbial composition, and ameliorate deficits in communicative, stereotypic, anxietylike, and sensorimotor behaviors in the offspring of MIA mice, a reliable animal model of
ASD (Hsiao et al., 2013). The MIA offspring exhibited altered serum metabolites of gut
origin that were normalized by B. fragilis treatment (Hsiao et al., 2013). Two of these
metabolites, 4EPS and indolepyruvate, are potentially associated with ASD (Hsiao et al.,
2013). Intestinal epithelial hyperpermeability, as well as altered levels of tight junction
proteins and cytokines, were also corrected by B. fragilis treatment. Hsiao et al. suggests that
B. fragilis is able to correct leaky gut by directly targeting tight junction expression, cytokine
production, and/or microbiome composition (Hsiao et al., 2013). This is consistent with the
role of gut microbiota in regulating metabolic homeostasis and intestinal permeability (Hsiao
et al., 2013). However, despite the improvements in communicative, repetitive, anxiety-like,
and sensorimotor behaviors, B. fragilis treatment fails to ameliorate deficits in sociability and
social preference (Hsiao et al., 2013).
2.Lactobacillus Reuteri
In a revolutionary and replicated study, Buffington et al. and Sgritta et al. found that
oral treatment with L. reuteri corrected oxytocin levels and synaptic dysfunction in the VTA
of MHFD offspring, a validated animal model for ASD (Buffington et al., 2016; Sgritta et al.,
2019). Buffington et al. was the first to complete this study and Sgritta et al. replicated this
study and examined possible mechanisms. Treatment with L. reuteri selectively ameliorates
social deficits in genetic, environmental, and idiopathic ASD models (Sgritta et al., 2019).
MHFD offspring who received L. reuteri treatment showed increases in reciprocal social
interactions, sociability, and preference for social novelty (Buffington et al., 2016). Only
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social deficits are ameliorated with L. reuteri treatment, no other behavioral endophenotypes
associated with ASD were affected (Buffington et al., 2016). Sgritta et al. also found that
treatment with L. reuteri corrects social deficits in several ASD mouse models (Sgritta et al.,
2019). The method in which L. reuteri alleviates social deficits was discovered to be via the
vagus nerve (Sgritta et al., 2019). A vagotomy prevented amelioration of social deficits
despite L. reuteri treatment (Sgritta et al., 2019). Vagal nerve fibers project to the
paraventricular nuclei (PVN), where oxytocin is produced, and subdiaphragmatic vagotomy
blocks this neural activity in the PVN (Sgritta et al., 2019). Additionally, Sgritta et al.
revealed that the effects of L. reuteri are not mediated by the restoration of the gut
microbiome as monocolonization in germ-free mice still successfully restored social
behaviors (Sgritta et al., 2019). Thus, L. reuteri treatment ameliorates social deficits and
related changes in synaptic function within the social reward neural circuits, in a vagus nerve
and oxytocin dependent manner (Sgritta et al., 2019).
The success of these probiotic interventions is contributable to two biological systems
linked to ASD pathology; the gastrointestinal system and the oxytocin system. To understand
the efficacy of B. fragilis in reducing repetitive behaviors, the relationship between ASD and
the GI system needs to be analyzed. Similarly, the oxytocin system must be addressed to
understand the efficacy of L. reuteri in ameliorating social deficits.

V. ASD and the GI system
An extensive study of over 14,000 individuals with ASD showed a higher prevalence
of irritable bowel syndrome (IBD) and other GI disorders in ASD subjects compared to
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controls (Kohane et al., 2012). The most reported GI symptoms in children with ASD are
“any GI symptom/aggregate of symptoms” (46.8%), constipation (22.0%), chronic diarrhea
(16.2%), and abdominal pain (14.0%) (Holingue et al., 2018). A study from the Childhood
Autism Risks from Genetics and Environment (CHARGE) revealed that frequency of GI
symptoms was associated with greater social withdrawal, stereotypy, irritability, and
hyperactivity (Vuong & Hsiao, 2017). Additional GI abnormalities associated with ASD
include altered gut microbiome composition, overproduction of bacterial metabolites, and
increased GI mucosa permeability (Azhari, Azizan, & Esposito, 2018). Adams et al. found
that ASD symptom severity is positively correlated with severity of GI dysfunction, a link
supported by various studies (Adams et al., 2011; Tomova et al., 2015; Yang et al., 2018).
The bidirectional relationship between the brain and the gut, also referred to as the
gut-brain axis, can influence development, neurochemistry, gene expression, and brain
function (Tomova et al., 2015). The gut microbiome, the most significant part of the GI
system, is comprised of 500-1000 denizen species representing 7,000-40,000 different strains
spanning 1800 genera and total to approximately 1x1013-1x1014 microorganisms (Rosenfeld,
2015). The gut microbiota is essential for digestion as it synthesizes various vitamins and
cofactors, and metabolizes complex lipids, proteins, and carbohydrates, even those that are
indigestible by the host (Rosenfeld, 2015).
Subjects with ASD have been repeatedly reported to have significant differences in
species richness and diversity, across phylum and species with a marked decrease in bacterial
diversity (Sharon, Sampson, Geschwind, & Mazmanian, 2016; Tomova et al., 2015; Kang et
al., 2017). A proposed explanation for this phenomenon is that many children with ASD
undergo increased oral antibiotic treatment during the first 3 years of life, which could
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destabilize their gut microbiome and create opportunities for competitive potential pathogens
to contribute to ASD severity (Kang et al., 2017). The gut microbiome becomes stable
between 6 and 36 months of life, thus the use of antibiotics could disrupt this critical process
(Mangiola et al., 2016). Children with ASD exhibit alteration in the Bacteroidetes/Firmicutes
ratio, even in comparison to neurotypical children with GI problems (Tomova et al., 2015).
Elevated levels of Clostridia, Desulfovibrio, Sutterella, Bacteriodetes, Lactobacillus,
Prevotella, Ruminococcus, and Alcaligenaceae have been found in the gut microbiomes of
ASD subjects (Tomova et al., 2015; Sharon, Sampson, Geschwind, & Mazmanian, 2016;
Rosenfeld, 2015; Mangiola et al., 2016). There is a very strong correlation between levels of
Desulfovibrio with the severity of ASD symptoms (Tomova et al., 2015). High levels of
Clostridia correlated with increased GI problems, within the ASD group (Ding, Taur, &
Walkup, 2017).
Gut dysbiosis can impact host immunity and neurobehavioral responses (Rosenfeld,
2015; Tomova et al., 2015). The gut microbiome directly and indirectly affects the intestinal
epithelium which, through the local mucosal immune system and enteric nervous system,
affects neuronal pathways from the gut to the brain (Tomova et al., 2015). Neuro-active
neurotransmitters, such as GABA, and short chain fatty acids (SCFA) are synthesized by the
gut microbiome and, through interactions upon the HPA (hypothalamic-pituitary-adrenal)
axis, can alter cognition and mood (Tomova et al., 2015). It has been suggested that
alterations in the gut microbiome could influence long-lasting changes in synaptic efficacy in
the mesolimbic dopamine reward system underlying social behaviors (Sgritta et al., 2019).
The epithelial gut barrier is critical to proper function as it controls the flow of
molecules between the GI tract and bloodstream and is maintained by tight junctions (Ding,
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Taur, & Walkup, 2017). These junctions can be affected by gut microbiota and their ligands
and can result in compromised integrity of the epithelial barrier, termed “leaky gut” (Ding,
Taur, & Walkup, 2017). Increased intestinal permeability can be problematic for the host as
it may allow for passage of bacteria, toxins, and metabolites into the bloodstream (Ding,
Taur, & Walkup, 2017). Increased bacterial translocation and direct measurements show
increased intestinal permeability in individuals with ASD (Whiteley, 2017; Hsiao et al.,
2013). In addition, altered levels of SCFAs, produced by gut microbiota, are capable of
passing through the BBB and have been noted in individuals with ASD (Azhari, Azizan, &
Esposito, 2018). Increased levels of SCFAs are notable because they can impact CNS
function via changes in neurotransmitter synthesis and release, mitochondrial function,
immune activation, lipid metabolism, and gene expression (Ding, Taur, & Walkup, 2017).
These neuroactive compounds have the ability to alter behavior once they pass through the
BBB and are in part, responsible for the abnormal behaviors prevalent in ASD. The
bidirectional relationship between the gut microbiome and the brain that allows for GI
impairments to result in abnormal behavior is depicted in Figure 2.
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Figure 2. The bidirectional relationship between the gut microbiome and the brain in the
pathology of ASD (Li, Han, Dy, & Hagerman, 2017).

VI. The Role of Oxytocin in ASD
Oxytocin is a nine-amino-acid neuropeptide produced in the hypothalamus with wellestablished neuroendocrine functions and remarkable influence over prosocial behavior
(Young & Barrett, 2015; Jones et al., 2017; Parker et al., 2017; Peñagarikano et al., 2015).
Oxytocin binds to four receptors: OXTR, V1AR, V1BR, and V2R though its prosocial
effects are associated with OXTR and V1AR (Parker et al., 2017). Oxytocin influences social
cognition, social behavior, fear conditioning, social attachment, pair bonding, and aggression
(Jones et al., 2017; Yamasue & Domes, 2018). Oxytocin expressing neurons in the PVN
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project to brain regions including the amygdala, hippocampus, and frontal cortex, that are
important in behaviors such as fear, memory, sociability, and attention (Peñagarikano et al.,
2015). Oxytocin increases the salience of social stimuli by activating VTA neurons and has
anxiolytic effects (Young & Barrett, 2015; Buffington et al., 2016; Jones et al., 2017).
Altered genotypes in oxytocin receptor genes have been associated with ASD symptomology
(Yamasue & Domes, 2018). In neurotypical subjects, there is a gradual shift of GABA action
from excitatory to inhibitory during development, termed “the GABA switch,” that when
interrupted, leads to ASD symptomology in animal models (Wagner & Harony-Nicolas,
2018).
Numerous studies regarding intranasal oxytocin intervention in ASD have been
completed. A replicated finding, intranasal administration of oxytocin temporarily enhances
social cognition, empathy, and reciprocity in individuals with ASD and increase social
behaviors such as eye gaze, feelings of rest, and recognition of affective speech (Young &
Barrett, 2015; Jones et al., 2017). Response to oxytocin treatment could be predicted by
pretreatment blood oxytocin levels, which suggests that a specific subset of the ASD
population could be more susceptible to improvements (Parker et al., 2017). The prosocial
effects of oxytocin have also been well-documented in animal models of ASD (Teng et al.,
2016; Peñagarikano et al., 2015; Wagner & Harony-Nicolas, 2018).
It is widely accepted that oxytocin administration is well-tolerated in humans and in
ASD populations specifically (Cai, Feng, & Yap, 2018; Parker et al., 2017). However,
possible adverse effects have been noted, such as altered sexual development, anaphylactic
shock, arrhythmia, nausea, and vomiting (Bales et al., 2013; Cai, Feng, & Yap, 2018). The
preferred method of targeting peptides to the brain is through intranasal administration, as it
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is less invasive of a procedure (Peñagarikano et al., 2015). Guastella and Hickie, noted that
children with poor verbal communication have difficulty tolerating nasal sprays, in their
unpublished data (Guastella and Hickie, 2016). Nasal discomfort, tiredness, irritability,
diarrhea, and skin irritation were the most common adverse reactions in children with ASD
using the intranasal method of oxytocin administration (Cai, Feng, & Yap, 2018). Still, there
are many discrepancies that need to be dealt with such as optimization of administration
route, dose, and treatment duration (Yamasue & Domes, 2018).

VII. The Current Study
Both B. fragilis and L. reuteri, bacterial strains present in the gut microbiome,
improve core symptoms of ASD (Hsiao et al., 2013; Buffington et al., 2016; Sgritta et al.,
2019). B. fragilis improves only restrictive and repetitive behaviors while L. reuteri improves
only social deficits (Hsiao et al., 2013; Buffington et al., 2016; Sgritta et al., 2019). With a
combination of the two probiotic strains, both repetitive behaviors and social deficits could
be targeted. I propose that probiotic intervention with B. fragilis will decrease restrictive and
repetitive behaviors in individuals with ASD. Similarly, I also expect that probiotic
intervention with L. reuteri will improve social deficits in individuals with ASD. I
extrapolate that, due to additive interaction effects, probiotic intervention with these two
bacterial strains will ameliorate both restrictive and repetitive behaviors and social deficits.
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VIII. Method
Participants
The participants will be children from the ages of 5 to 13 that have been clinically
diagnosed with ASD and have no other neurological comorbidities.
Materials
Bacteroides fragilis in capsule form, Lactobacillus reuteri in capsule form, placebo
capsules
Measures
Repetitive and Restrictive Behavior
Repetitive and restrictive behavior will be measured by the Repetitive Behavior Scale
– Revised (RBS-R). This scale measures the severity of repetitive behaviors in individuals
with ASD. The 43 items are organized into six subscales: stereotyped behavior, self-injurious
behavior, compulsive behavior, ritualistic behavior, sameness behavior, and restricted
behavior (Scahill et al., 2015). The items are scored on a four-point scale from zero to three
(0=never, 1=mild, 2=moderate, 3=severe) (Scahill et al., 2015). I propose to use the RBS-R
total score, out of 129, to measure repetitive and restricted behavior.
Social Deficits
Social ability, and consequently social deficits, will be measured by the Social
Responsiveness Scale (SRS-2). This scale assesses the individual’s ability to engage in
appropriate reciprocal social interaction and communication (Frazier et al., 2014). The SRS-2
is comprised of 5 subscales: social awareness (assesses an individual’s ability to recognize
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social cues of others), social cognition (assesses interpretation of social behavior), social
communication (assesses reciprocal communication in social situations), and autistic
mannerisms (assesses stereotypy and restrictive interests) (Frazier et al., 2014; Bruni, 2014).
Items are scored on a scale from one (never) to four (almost always). The results of the SRS2 are reported in T-score format (M=50, SD=10) (Bruni, 2014). The SRS-2 total score is the
most reliable form of assessing social deficits in individuals with autism (Bruni, 2014). Thus,
I will use this scale to quantify social deficit in ASD individuals in the current study.
Procedures
There will be four experimental groups. The first is the control group who will take
two placebo capsules. The second group will take one capsule of B. fragilis and one placebo
capsule. The third group will take one capsule of L. reuteri and one placebo capsule. The
fourth group will take one capsule of B. fragilis and one capsule of L. reuteri. All groups will
take the capsules orally, once a day with breakfast. Caretakers will assess the participants
using the RBS-R and the SRS-2 scales three times a week. The children will also participate
in an academic medical center-based program for families with ASD that focuses on
integrations of interventions, clinical trials, and childcare. The children will visit the center
weekly, allowing blinded researchers to assess the participants using the RBS-R and SRS-2
scales. The study will proceed for the duration of a year, allowing for short term and longterm observations to be made.
Ethics
As this study involves human participants, the study must be approved by the
Institutional Review Board at Scripps College in accordance with the currently applicable
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U.S. Public Health Service Guidelines. Additionally, this study involves children with
cognitive impairment and they are considered a protected and vulnerable population. Thus,
informed consent will need to be provided by the legal guardians of the children. The
participants must be children with ASD as that is the target population of this intervention
and its efficacy must be examined in the ASD population. Furthermore, most treatment
interventions for ASD occur in childhood, underscoring the importance of evaluating the
efficacy of this probiotic intervention in children with ASD.

IX. Expected Results
Those in the control group will see no improvement in repetitive behavior or social
deficits. Those receiving only B. fragilis will see improvements in repetitive behavior but not
in social deficits. Those receiving only L. reuteri will see improvements in social deficits but
not in repetitive behavior. Those taking both strains will see improvements in both repetitive
behavior and social deficits.
The mean RBS-R score for individuals with autism is 33.14 (Lam). All experimental
groups will begin the intervention with mean RBS-R scores of 33.14. Those receiving the
placebo or L. reuteri interventions will not see an improvement in repetitive behaviors and
their RBS-R scores will not be significantly altered. The placebo intervention group will end
with a mean RBS-R score of 33.67 and the L. reuteri intervention group will end with a mean
RBS-R score of 34.59. Those receiving the B. fragilis or both probiotic strains intervention
will see a reduction of repetitive behaviors, manifesting in lower mean RBS-R scores. The B.
fragilis intervention group will end with a mean RBS-R score of 15.47 and the intervention
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with both probiotic strains will end with a mean RBS-R score of 16.13. These expected
scores are represented in Figure 3.
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Figure 3. Change in RBS-R scores after differing interventions.
SRS-2 T-scores are correlated with severe, moderate, and mild social deficits. Severe
and clinically significant social deficits are indicated by T-scores 76 or higher (Bruni, 2014).
The moderate range of T-scores falls between 66 and 75 and demonstrates some clinically
significant social deficits (Bruni, 2014). Scores between 60 to 65 indicate mild social
impairments (Bruni, 2014).
The mean SRS-2 T-score of all participants before intervention will be 77. Those
receiving the placebo intervention will have no significant reduction in mean SRS-2 T-scores
and will end the intervention with a T-score of 76. Those receiving the B. fragilis
intervention will also see no improvement in social deficits, manifesting in a final SRS-2 Tscore of 77. The individuals receiving the L. reuteri intervention will see significant
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improvement in social deficits and end with a significantly lower SRS-2 T-score of 62. The
individuals receiving the intervention with both probiotic strains will also see a significantly
lower mean SRS-2 T-score of 63 as well as improvements in social deficits. Thus, the
placebo and B. fragilis interventions will not affect social deficits but the L. reuteri and
combined strains intervention will improve social deficits. These expected scores are
represented in Figure 4.
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Figure 4. Change in SRS-2 scores after differing interventions.

X. Discussion
Implications
If probiotic intervention with B. fragilis and L. reuteri is found to be viable and
effective, it would significantly affect the lives of individuals with ASD and their families.
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This would become the first intervention to target the core symptoms of ASD, repetitive
behavior and social deficits. Furthermore, it could substantially decrease the economic
burden associated with ASD. The estimated total costs per year for children with ASD falls
between $11.5 - $60.9 billion (2011 US dollars) which includes indirect and direct expenses
such as, medical care, loss of parental economic productivity, and special education (CDC,
2018). The most effective intervention to date, early intensive behavioral therapy, can cost
nearly $40,000 - $60,000 per year (CDC, 2018). If this probiotic intervention is found to be
effective, it could provide a more economically accessible avenue of intervention for
individuals with ASD, as probiotic production costs are notably lower than pharmaceutical
production costs and behavioral therapy sessions. Additionally, daily oral administration
would take less time than in-person therapy sessions which could prevent the loss of parental
economic productivity. Although probiotic intervention would not necessarily or directly
improve the general health of an individual with ASD, it could improve behaviors that are
indirectly detrimental to health, such as maintaining a narrow food repertoire and
uncontrolled motor stereotypies. This reduction in restrictive and repetitive behavior would
reduce the need for individuals to resort to costly medications associated with negative side
effects, such as risperidone, which is used to treat irritability in individuals with ASD in the
hopes of preventing injurious and self-injurious motor stereotypies. Another pertinent issue
that has yet to be addressed by current interventions is the treatment of adults with ASD.
Most of the available treatments for ASD are targeted towards children, resulting in a
significant decline in effectiveness with increasing age. Teng et al., found that oxytocin
administration improved social deficits in both young and adult mice, in an age-independent
manner (Teng et al., 2016). Since L. reuteri administration stimulates oxytocin production, it
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is comparable to and less invasive than intranasal oxytocin administration. Thus, it could be
expected that the prosocial effect of L. reuteri would also be age-independent. If this were
the case, this would allow adults with ASD to receive effective treatment for their social
communication deficits which could potentially lead to an increase in independence, both
economically and physically. However, if this combined probiotic treatment of B. fragilis
and L. reuteri were to be established as ineffective in humans, the biological, economical,
and social state of individuals with ASD would remain the same and there would be no
interventions targeted towards the core symptoms of ASD.
Possible Complications
A few different factors could complicate the application of this probiotic intervention
in the treatment of ASD. Most importantly, the most effective dosages of B. fragilis and L.
reuteri have yet to be determined. There is potential that the most effective dose could vary
among specific populations of individuals with ASD. It has been determined that there are
specific subsets of individuals with ASD, attributed to different geneses, with predispositions
to comorbidities and intervention effectiveness (Parker et al., 2017). It is possible that a
specific endotype of individuals with ASD will be more susceptible to improvements through
probiotic intervention, although biological markers differentiating these subsets have not yet
been determined. Additionally, it is possible that there is optimum dosage ratio of B. fragilis
to L. reuteri as both strains, to be effective, must colonize the gut microbiome and little is
known about whether there would be competition between the two strains during the
colonizing process. The optimal length of intervention could differ between the two strains
and it is not yet known if improvements in behavioral and social deficits are dependent upon
continued oral administration.
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Future Studies
It is imperative that studies ascertain the optimal clinical dosage of B. fragilis and L.
reuteri, both independently and concurrently. These findings would lay the foundation for
future improvements and adjustments of this intervention method. In addition, future studies
must examine differing lengths of probiotic intervention and the following period after
discontinuation to explore the temporal dependency of improvements upon daily
administration. Furthermore, Hsiao et al., found that improvements in repetitive and
restrictive behavior could be induced by other probiotic strains and was not singularly
dependent upon B. fragilis intervention (Hsiao et al., 2013). The probiotic strain Bacteroides
thetatiotacomicron also significantly improved restrictive and repetitive behaviors in MIA
offspring although the administration of the probiotic strain Enterococcus faecalis did not
have any effect on behavior, signifying that there is some level of specificity to efficacy of
probiotic intervention.

XI. Conclusions
Treatment with B. fragilis decreases restrictive and repetitive behaviors by correcting
intestinal epithelial hyperpermeability, cytokine production, and gut microbiome composition
(Hsiao et al., 2013). B. fragilis treatment targets the tight junction protein expression of the
intestinal epithelium, and improves intestinal barrier integrity (Hsiao et al., 2013). This
decreases leakage of neuro-active molecules into the blood that can lead to abnormal
behaviors (Hsiao et al., 2013). Treatment with L. reuteri ameliorates social deficits by
stimulating oxytocin production via the vagus nerve which increases oxytocin levels and
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restores social interaction-induced synaptic plasticity (Sgritta et al., 2019). The increase in
oxytocin levels promotes prosocial behavior and increases reciprocal social interactions,
sociability, and preference for social novelty (Sgritta et al., 2019). It is hypothesized that
treatment with both probiotic strains will decrease behavioral and social deficits, the core
symptoms of ASD that have not yet been addressed by available interventions to date.
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